Viral, inflammatory, and reservoir characteristics of posttreatment controllers.
Journal
Current opinion in HIV and AIDS
ISSN: 1746-6318
Titre abrégé: Curr Opin HIV AIDS
Pays: United States
ID NLM: 101264945
Informations de publication
Date de publication:
01 09 2021
01 09 2021
Historique:
pubmed:
3
8
2021
medline:
26
8
2021
entrez:
2
8
2021
Statut:
ppublish
Résumé
To provide an overview of studies to date that have identified posttreatment controllers (PTCs) and to explore current evidence around clinical characteristics, immune effector function, and inflammatory and viral reservoir characteristics that may underlie the control mechanism. PTCs are broadly defined as individuals capable of maintaining control of HIV replication after cessation of antiretroviral therapy (ART). While starting ART early after HIV infection is associated with PTC, genetic disposition or CD8+ T-cell function do not appear to explain this phenomenon, but these features have not been exhaustively analyzed in PTCs. A lower frequency of latently infected cells prior to stopping ART has been associated with achieving PTC, including a lower level of intact HIV DNA, but more studies are needed to map the genetic location, epigenetic characteristics, and tissue distribution of the intact HIV reservoir in PTCs. Current studies are small and heterogeneous and there is a significant need to agree on a uniform definition of PTC. Many aspects of PTC are still unexplored including whether specific features of genetic disposition, immune effector functions, and/or viral reservoir characteristics play a role in PTC. A large multisite international cohort study could aide in providing the important insights needed to fully understand PTC.
Identifiants
pubmed: 34334614
doi: 10.1097/COH.0000000000000699
pii: 01222929-202109000-00004
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
249-256Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Walker BD, Yu XG. Unravelling the mechanisms of durable control of HIV-1. Nat Rev Immunol 2013; 13:487–498.
Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007; 27:406–416.
Etemad B, Esmaeilzadeh E, Li JZ. Learning from the exceptions: HIV remission in posttreatment controllers. Front Immunol 2019; 10:1749.
Martin GE, Frater J. Posttreatment and spontaneous HIV control. Curr Opin HIV AIDS 2018; 13:402–407.
Sáez-Cirión A, Bacchus C, Hocqueloux L, et al. Posttreatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013; 9:e1003211.
Collins DR, Gaiha GD, Walker BD. CD8(+) T cells in HIV control, cure and prevention. Nat Rev Immunol 2020; 20:471–482.
Sharaf R, Lee GQ, Sun X, et al. HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers. J Clin Invest 2018; 128:4074–4085.
Goulder P, Deeks SG. HIV control: is getting there the same as staying there? PLoS Pathog 2018; 14:e1007222.
Samri A, Bacchus-Souffan C, Hocqueloux L, et al. Polyfunctional HIV-specific T cells in post-treatment controllers. AIDS 2016; 30:2299–2302.
Fidler S, Olson AD, Bucher HC, et al. Virological blips and predictors of post treatment viral control after stopping ART started in primary HIV infection. J Acquir Immune Defic Syndr 2017; 74:126–133.
Namazi G, Fajnzylber JM, Aga E, et al. The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: posttreatment controllers identified from 14 clinical studies. J Infect Dis 2018; 218:1954–1963.
Hocqueloux L, Prazuck T, Avettand-Fenoel V, et al. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS 2010; 24:1598–1601.
Gianella S, von Wyl V, Fischer M, et al. Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA. Antivir Ther 2011; 16:535–545.
Goujard C, Girault I, Rouzioux C, et al. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy. Antivir Ther 2012; 17:1001–1009.
Lodi S, Meyer L, Kelleher AD, et al. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med 2012; 172:1252–1255.
Stöhr W, Fidler S, McClure M, et al. Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy. PLoS One 2013; 8:e78287.
Maenza J, Tapia K, Holte S, et al. How often does treatment of primary HIV lead to posttreatment control? Antivir Ther 2015; 20:855–863.
Martin GE, Gossez M, Williams JP, et al. Posttreatment control or treated controllers? Viral remission in treated and untreated primary HIV infection. AIDS 2017; 31:477–484.
Van Gulck E, Bracke L, Heyndrickx L, et al. Immune and viral correlates of ‘secondary viral control’ after treatment interruption in chronically HIV-1 infected patients. PLoS One 2012; 7:e37792.
Calin R, Hamimi C, Lambert-Niclot S, et al. Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir. AIDS 2016; 30:761–769.
Assoumou L, Weiss L, Piketty C, et al. A low HIV-DNA level in peripheral blood mononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral control. AIDS 2015; 29:2003–2007.
Perkins MJ, Bradley WP, Lalani T, et al. Brief report: prevalence of posttreatment controller phenotype is rare in HIV-infected persons after stopping antiretroviral therapy. J Acquir Immune Defic Syndr 2017; 75:364–369.
Maggiolo F, Di Filippo E, Comi L, Callegaro A. Posttreatment controllers after treatment interruption in chronically HIV-infected patients. AIDS 2018; 32:623–628.
Gianella S, Anderson CM, Richman DD, et al. No evidence of posttreatment control after early initiation of antiretroviral therapy. AIDS 2015; 29:2093–2097.
Sneller MC, Justement JS, Gittens KR, et al. A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection. Sci Transl Med 2017; 9:eaan8848doi: 10.1126/scitranslmed.aan8848.
doi: 10.1126/scitranslmed.aan8848
Ugarte A, Romero Y, Tricas A, et al. Unintended HIV-1 infection during analytical therapy interruption. J Infect Dis 2020; 221:1740–1742.
Henrich TJ, Hatano H, Bacon O, et al. HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: an observational study. PLoS Med 2017; 14:e1002417.
Henrich TJ, Hanhauser E, Marty FM, et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med 2014; 161:319–327.
Luzuriaga K, Gay H, Ziemniak C, et al. Viremic relapse after HIV-1 remission in a perinatally infected child. N Engl J Med 2015; 372:786–788.
Colby DJ, Trautmann L, Pinyakorn S, et al. Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection. Nat Med 2018; 24:923–926.
Pannus P, Rutsaert S, De Wit S, et al. Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal on-going viral transcription. J Int AIDS Soc 2020; 23:e25453.
Williams JP, Hurst J, Stöhr W, et al. HIV-1 DNA predicts disease progression and posttreatment virological control. Elife 2014; 3:e03821.
Li JZ, Etemad B, Ahmed H, et al. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS 2016; 30:343–353.
Jiang C, Lian X, Gao C, et al. Distinct viral reservoirs in individuals with spontaneous control of HIV-1. Nature 2020; 585:261–267.
Einkauf KB, Lee GQ, Gao C, et al. Intact HIV-1 proviruses accumulate at distinct chromosomal positions during prolonged antiretroviral therapy. J Clin Invest 2019; 129:988–998.
Cohn LB, Chomont N, Deeks SG. The biology of the HIV-1 latent reservoir and implications for cure strategies. Cell Host Microbe 2020; 27:519–530.
Peluso MJ, Bacchetti P, Ritter KD, et al. Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy. JCI Insight 2020; 5:e132997doi: 10.1172/jci.insight.132997.
doi: 10.1172/jci.insight.132997
Simonetti FR, White JA, Tumiotto C, et al. Intact proviral DNA assay analysis of large cohorts of people with HIV provides a benchmark for the frequency and composition of persistent proviral DNA. Proc Natl Acad Sci USA 2020; 117:18692–18700.
Veenhuis RT, Kwaa AK, Garliss CC, et al. Long-term remission despite clonal expansion of replication-competent HIV-1 isolates. JCI Insight 2018; 3:e122795doi: 10.1172/jci.insight.122795.
doi: 10.1172/jci.insight.122795
Woldemeskel BA, Kwaa AK, Blankson JN. Viral reservoirs in elite controllers of HIV-1 infection: implications for HIV cure strategies. EBioMedicine 2020; 62:103118.
Offersen R, Yu WH, Scully EP, et al. HIV antibody Fc N-linked glycosylation is associated with viral rebound. Cell Rep 2020; 33:108502.
Giron LB, Papasavvas E, Azzoni L, et al. Plasma and antibody glycomic biomarkers of time to HIV rebound and viral setpoint. AIDS 2020; 34:681–686.
Giron LB, Papasavvas E, Yin X, et al. Phospholipid metabolism is associated with time to HIV rebound upon treatment interruption. mBio 2021; 12:e03444-20doi: 10.1128/mBio.03444-20.
doi: 10.1128/mBio.03444-20
Giron LB, Palmer CS, Liu Q, et al. Noninvasive plasma glycomic and metabolic biomarkers of posttreatment control of HIV. Nat Commun 2021; 12:3922.
Crowell TA, Fletcher JL, Sereti I, et al. Initiation of antiretroviral therapy before detection of colonic infiltration by HIV reduces viral reservoirs, inflammation and immune activation. J Int AIDS Soc 2016; 19:21163.
Ananworanich J, Chomont N, Eller LA, et al. HIV DNA set point is rapidly established in acute HIV infection and dramatically reduced by early ART. EBioMedicine 2016; 11:68–72.
Deng K, Pertea M, Rongvaux A, et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 2015; 517:381–385.
Cao W, Mehraj V, Trottier B, et al. Early initiation rather than prolonged duration of antiretroviral therapy in HIV infection contributes to the normalization of CD8 T-cell counts. Clin Infect Dis 2016; 62:250–257.
Takata H, Buranapraditkun S, Kessing C, et al. Delayed differentiation of potent effector CD8(+) T cells reducing viremia and reservoir seeding in acute HIV infection. Sci Transl Med 2017; 9:eaag1809doi: 10.1126/scitranslmed.aag1809.
doi: 10.1126/scitranslmed.aag1809
Van Hecke C, Trypsteen W, Malatinkova E, et al. Early treated HIV-1 positive individuals demonstrate similar restriction factor expression profile as long-term nonprogressors. EBioMedicine 2019; 41:443–454.